Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Long-term follow-up of patients with relapsed or refractory non-Hodgkin’s lymphoma receiving allogeneic stem cell transplantation

Bone Marrow Transplantation volume 51, pages 1527–1529 (2016)Cite this article

Subjects

While the majority of patients with chemosensitive aggressive B-cell lymphoma (BCL) can be cured by immunochemotherapy or by autologous stem cell transplantation (SCT), the prognosis is dismal in refractory disease, mantle cell or advanced indolent lymphoma and peripheral T-cell lymphoma (PTCL).1 For these patients, allogeneic SCT is regarded as a therapeutic option.1, 2, 3 Although allogeneic SCT is a potential curative approach, its application requires careful consideration as transplant-related mortality remains significant and the outcome after transplantation is influenced by various disease and treatment related factors.2, 4, 5, 6 With a large number of upcoming new drugs for non-Hodgkin’s lymphoma (NHL), long-term survival data are needed to help to decide between treatment options. This study aims to describe the long-term outcome with 10-year survival data of patients receiving allogeneic SCT for NHL in a German university hospital setting.

This retrospective study included 89 patients with relapsed or refractory B or T-cell lymphoma who received their first allogeneic stem cell transplantation between 1995 and 2011 at Dresden University Hospital. The study design was approved by the local ethics committee (EK 382122012). Last follow-up was in January 2014. Patients were assigned to one of four different cohorts according to their histology: mantle cell lymphoma (MCL), indolent B-cell lymphoma (IBCL), aggressive B-cell lymphoma (ABCL) and PTCL. Detailed patient characteristics are presented in Table 1.

Table 1 Characteristics of the study population
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Chao MP . Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res 2013; 5: 251–269.

    Article  Google Scholar 

  2. Nademanee A . Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol 2009; 2: 425–442.

    Article  Google Scholar 

  3. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  Google Scholar 

  4. Gkotzamanidou M, Papadimitriou CA . Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 2014; 89: 248–261.

    Article  Google Scholar 

  5. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547–553.

    Article  Google Scholar 

  6. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554–563.

    Article  Google Scholar 

  7. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  8. Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M et al. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia 2012; 26: 1779–1785.

    Article  CAS  Google Scholar 

  9. Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008; 42: 601–608.

    Article  CAS  Google Scholar 

  10. Bertz H, Illerhaus G, Veelken H, Finke J . Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 135–139.

    Article  CAS  Google Scholar 

  11. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  12. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951–3958.

    Article  Google Scholar 

  13. Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015; 26: 386–392.

    Article  CAS  Google Scholar 

  14. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.

    Article  Google Scholar 

  15. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520–526.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge Catrin Theuser for technical assistance.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

    C S Link, F Mies, J Scheele, M Kramer, J Schetelig, R Ordemann, M Bornhäuser, G Ehninger & F Kroschinsky

  2. Klinik für Innere Medizin III, Klinikum Chemnitz gGmbH, Chemnitz, Germany

    F Mies & M Hänel

Authors
  1. F Mies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Scheele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Schetelig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Ordemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Hänel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Bornhäuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Kroschinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C S Link.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Link, C., Mies, F., Scheele, J. et al. Long-term follow-up of patients with relapsed or refractory non-Hodgkin’s lymphoma receiving allogeneic stem cell transplantation. Bone Marrow Transplant 51, 1527–1529 (2016). https://doi.org/10.1038/bmt.2016.165

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.165

Search

Advanced search

Quick links